Management of Rising PSA in Men on Testosterone Replacement Therapy

Assessment and Diagnosis

• The American College of Physicians and other medical guidelines recommend prostate biopsy for men on testosterone replacement therapy (TRT) who experience a yearly PSA increase of 1.0 ng/ml or more, as seen in this patient with a PSA increase of 1.89 ng/ml 1, 2, 3
• Men with a family history of prostate cancer, such as this patient with a brother who has prostate cancer, should have a lower threshold for biopsy while on TRT 4
• The pattern of PSA increase, rather than the absolute value, is concerning and warrants further investigation, with a threshold of 1.0 ng/ml increase over the monitoring period 1, 2, 5

Monitoring and Follow-up

• The American Urological Association recommends continuing TRT with close monitoring, performing PSA testing every 3-6 months, and conducting digital rectal examination at each follow-up for men on TRT with a negative biopsy 1, 2, 5, 6
• Consider repeat biopsy if PSA continues to rise by more than 0.4 ng/ml/year, as this may indicate underlying prostate cancer 2, 7

Evidence-Based Rationale

• The New England Journal of Medicine guidelines specifically recommend prostate biopsy for men on TRT who experience PSA increases of 0.7-0.9 ng/ml, with repeat PSA measurement in 3-6 months and biopsy if any further increase occurs 2, 3
• The mean numerical increase in PSA with TRT is typically only 0.30-0.43 ng/ml, and this patient's increase is substantially higher, warranting investigation 2

Testosterone Replacement Therapy and Prostate Cancer Risk

Introduction to PSA Monitoring

• The American College of Physicians recommends that any PSA increase of ≥1.0 ng/ml per year on TRT mandates prostate biopsy, although specific guidelines may vary 8

PSA Changes with Testosterone Therapy

• Among hypogonadal men with normal PSA and digital rectal exam who underwent prostate biopsy before starting TRT, 14% had occult prostate cancer (median age 64 years), highlighting the importance of baseline assessment 8
• Prostate volume increases significantly during the first six months of TRT to levels equivalent to eugonadal men, but this does not correlate with urinary symptoms or cancer risk, as observed in a study published in the New England Journal of Medicine 8

Clinical Algorithm for PSA Monitoring

• The New England Journal of Medicine suggests monitoring PSA every 3-6 months initially, then every 6-12 months if stable, during TRT, to promptly identify potential prostate cancer cases 8

Testosterone Replacement Therapy: Prostate Cancer Risk and Monitoring

Prostate Cancer Risk

• Current high‑quality evidence shows no compelling causal link between testosterone exposure (including TRT) and the development of prostate cancer in men. 9
• Long‑term cohort analyses of stored plasma samples found identical baseline testosterone concentrations in men who later developed prostate cancer (7–25 years after sampling) and those who remained cancer‑free. 9
• A systematic review of 12 prospective studies concluded that serum androgen levels are not significantly associated with subsequent prostate cancer incidence. 9
• Epidemiologic data demonstrate that prostate cancer incidence rises as endogenous testosterone levels naturally decline with advancing age, contradicting a hypothesis of testosterone‑driven carcinogenesis. 9
• TRT can reveal previously occult prostate malignancies (by modestly increasing PSA) rather than initiating new cancers; occult disease was identified in a notable proportion of screened hypogonadal men. 9

Recommended Baseline Evaluation Before Initiating TRT

• Obtain a baseline prostate‑specific antigen (PSA) measurement and perform a digital rectal examination (DRE) in all men considered for TRT. 9
• If the baseline PSA exceeds 4.0 ng/mL or the DRE reveals suspicious findings (e.g., nodules, asymmetry, increased firmness), a prostate biopsy should be performed prior to starting TRT. 9

Ongoing Monitoring During TRT

• Maintain a low threshold for repeat prostate biopsy whenever the DRE shows any new or worsening abnormalities during therapy. 9

Note: The source article characterizes the underlying evidence as “the highest quality evidence available,” indicating a strong level of confidence in these recommendations.